Monoclonal anti-D development programme
BM Kumpel - Transplant immunology, 2002 - Elsevier
Administration of anti-D immunoglobulin to D− women after delivery of a D+ infant has
dramatically reduced the number of immunised women and cases of haemolytic disease of
the fetus and newborn. The use of monoclonal anti-D might alleviate some of the pressures
on maintaining adequate supplies of plasma sourced anti-D. Two human monoclonal
antibodies, BRAD-3 (IgG1) and BRAD-5 (IgG3), with proven activity in in vitro functional
(immunological) assays with cells bearing IgG Fc receptors (FcγR) were selected for clinical …
dramatically reduced the number of immunised women and cases of haemolytic disease of
the fetus and newborn. The use of monoclonal anti-D might alleviate some of the pressures
on maintaining adequate supplies of plasma sourced anti-D. Two human monoclonal
antibodies, BRAD-3 (IgG1) and BRAD-5 (IgG3), with proven activity in in vitro functional
(immunological) assays with cells bearing IgG Fc receptors (FcγR) were selected for clinical …
